Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01276691 · ClinicalTrials.gov registry record · Phase 4
Effect of Aspirin on Hemostatic and Vascular Function After Live Fire Fighting
A Phase 4 study of Cardiovascular Risk Factor and C.Medical Procedure; Vascular, Functional or Late, sponsored by University of Illinois at Urbana-Champaign.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01276691: Completed Phase 4 study of Cardiovascular Risk Factor and C.Medical Procedure; Vascular, Functional or Late, sponsored by University of Illinois at Urbana-Champaign.
NCT01276691 is a Phase 4 study of Cardiovascular Risk Factor and C.Medical Procedure; Vascular, Functional or Late that has completed, run by University of Illinois at Urbana-Champaign. The registered enrollment target is 24 participants, below the 3,067-participant average among 31 other Cardiovascular Risk Factor trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01276691, a Phase 4 study of Cardiovascular Risk Factor and C.Medical Procedure; Vascular, Functional or Late, has completed, sponsored by University of Illinois at Urbana-Champaign.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators hypothesize that 1. an acute treatment of low-dose aspirin will lead to a) decreased resting platelet activation, platelet aggregation, and clotting potential, b) increased fibrinolytic potential following fire fighting, c) no significant effect on endothelial function or arterial stiffness versus the placebo condition. 2. chronic treatment with low-dose aspirin will lead to a) decreased resting and fire fighting induced platelet activation, platelet aggregation, clotting potential, b) increased fibrinolytic potential, and c) increased endothelial function and decreased arterial stiffness in response to live fire fighting versus the placebo condition. 3. short-term fire fighting activity will result in: a) a reduction in arterial function (reduced endothelial function, increased augmentation index and an attenuated arterial stiffness response); b) a disruption in hemostasis that is characterized by an increase in platelet number and function, an increased coagulatory potential and altered fibrinolytic potential; and c) an elevation in procoagulatory cytokines, systemic inflammation, monokine chemoattractant protein, and matrix metalloproteinases.
Primary Outcome
Vascular function will be assessed via pulse wave analysis, pulse wave velocity, carotid artery compliance, beta stiffness index, forearm rsistance artery vasodilatory capacity, and brachial artery blood flow.
Conditions Studied
Interventions
- DRUG 81 mg enteric coated aspirin
Study Locations (1)
Illinois
- Illinois Fire Service Institute - Champaign
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-02 |
| Est. Completion | 2012-12 |
| Phase | Phase 4 |
What the finished NCT01276691 record still lists
NCT01276691 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 3,067-participant average among 31 other Cardiovascular Risk Factor trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Cardiovascular Risk Factor appearing as the primary indexed condition, and to 1 intervention - of which 81 mg enteric coated aspirin is the first listed.
NCT01276691 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT01276691 about?
NCT01276691 is a clinical study titled "Effect of Aspirin on Hemostatic and Vascular Function After Live Fire Fighting". The investigators hypothesize that 1. an acute treatment of low-dose aspirin will lead to a) decreased resting platelet activation, platelet aggregation, and clotting potential, b) increased fibrinolytic potential following fire fighting, c) no significant effect on endothelial function or arterial...
What is the current status of trial NCT01276691?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2011-02. Estimated completion is 2012-12.
What conditions does trial NCT01276691 study?
This clinical trial studies the following conditions: Cardiovascular Risk Factor, C.Medical Procedure; Vascular, Functional or Late, Electrolyte and Fluid Balance Conditions.
What interventions are being tested in trial NCT01276691?
The interventions under investigation include: 81 mg enteric coated aspirin (DRUG).
Who is sponsoring clinical trial NCT01276691?
This trial is sponsored by University of Illinois at Urbana-Champaign, which has 129 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01276691 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Risk Factor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01276691's enrollment target sits among peer trials
24 28th of 31 higher than 3 of 31 other Cardiovascular Risk Factor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Risk Factor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
RECRUITING · NA
-
Community Benefit of No-charge Calcium Score Screening Program
RECRUITING
-
Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure
RECRUITING
-
The Influence of Mitochondrial-Derived Reactive Oxygen Species on Racial Disparities in Neurovascular Function
RECRUITING · NA
-
Sleep Duration and Cardiovascular Health
RECRUITING · NA
-
The Potassium Supplementation Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia